Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Patient's own blood plasma kickstart ovulation in PCOS?

NCT ID NCT07777640

Disease control Sponsor: Bangladesh Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether injecting a woman's own platelet-rich plasma (PRP) into her ovaries can help trigger ovulation better than standard hormone injections (gonadotropin) in women with polycystic ovary syndrome (PCOS) who haven't responded to the fertility drug letrozole. Participants are randomly assigned to receive either PRP via laparoscopy or gonadotropin injections, then monitored for three cycles to compare follicle development, ovulation, and pregnancy rates. The goal is to find a more effective or less hormonal option for this hard-to-treat group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Autologous platelet-rich plasma (PRP) injected into the ovaries, compared with gonadotropin (recombinant FSH and hMG) injections.
What this could lead to
If PRP works, it could offer a less hormonal alternative to stimulate ovulation in women with PCOS who don't respond to standard fertility drugs, potentially improving pregnancy chances.
What could go wrong
This is a small, early-stage trial, and PRP's effectiveness is uncertain. Risks include the invasiveness of laparoscopic injection and the possibility that PRP may not improve ovulation or pregnancy rates compared to standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Jun 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18-35 years diagnosed with polycystic ovary syndrome (PCOS) based on the Rotterdam criteria. * Primary or secondary subfertility. * Patients with a history of letrozole resistance (failure to ovulate with standard dose of letrozole). Exclusion Criteria: * Body Mass Index (BMI) \<18.5 kg/m² or ≥30 kg/m². * Presence of other causes of infertility (e.g., endometriosis, tubal factor, severe male factor infertility). * Patients with uncontrolled endocrine disorders (e.g., thyroid dysfunction, hyperprolactinemia). * Any contraindication to platelet-rich plasma (PRP) therapy (coagulation disorder or current use of anticoagulant). * Patient not fit for surgery. * Hypersensitivity to gonadotropin.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polycystic ovary syndrome (PCOS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polycystic ovary syndrome (PCOS)

Contacts and locations

Locations

  • Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University

    Dhaka, Dhaka Division, 1000, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.